Skip to content

Veracyte VCYT HTM Securities

HTM Securities at other companies

Clover Health Investments logo
Clover Health InvestmentsCLOV
$14.24M-0.1%
First Hawaiian, Inc. logo
First Hawaiian, Inc.FHB
$3.48B-6.6%
Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$10M
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$588.75M+354%
Associated Banc-Corp logo
Associated Banc-CorpASB
$3.57B-3.6%
Ameris Bancorp logo
Ameris BancorpABCB
$202.55M+16.6%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's htm securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's HTM securities?
Veracyte (VCYT) reported HTM securities of $175.92M in Q1 2026.
How has Veracyte's HTM securities changed year-over-year?
Veracyte's HTM securities increased by 73.8% year-over-year, from $101.24M to $175.92M.
What is the long-term trend for Veracyte's HTM securities?
Over 4 years (2021 to 2025), Veracyte's HTM securities has grown at a 88.3% compound annual growth rate (CAGR), from $4M to $50.31M.
What does HTM securities mean?
Debt securities the company intends and is able to hold until maturity, carried at amortized cost rather than fair value.